Updated Jul 16, 2026 · Last SEC filing 2026-07-07
Xeris Biopharma Holdings, Inc. (XERS) has filed 12 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-07. 5 Form 8-K material event filings were reported by XERS in the last 90 days. 8 Form 144 notices of proposed sale were filed for XERS stock. InsiderAlpha tracks every XERS SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Pharmaceutical Preparations (SIC 2834) |
|---|---|
| SEC CIK | 0001867096 |
| Form 4 filings (90d) | 12 |
|---|---|
| Form 8-K filings (90d) | 5 |
| Form 144 notices (90d) | 8 |
| Latest Form 4 filing | 2026-07-07 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Pieper Steven | See Remarks | S — Open-market sale | 27.6K | $8.52 | $235K | SEC | |
| Pieper Steven | See Remarks | S — Open-market sale | 17.4K | $8.50 | $148K | SEC | |
| KREHER NERISSA | Director | A — Grant or award | 33.6K | $0.00 | — | SEC | |
| Hecht Beth | See Remarks | S — Open-market sale | 16.7K | $8.03 | $134K | SEC | |
| McCulloch Kevin | See Remarks | S — Open-market sale | 90.0K | $8.03 | $723K | SEC | |
| BORMANN-KENNEDY BARBARA-JEAN ANNE | Director | A — Grant or award | 24.2K | $0.00 | — | SEC | |
| HALKUFF DAWN | Director | S — Open-market sale | 20.0K | $6.09 | $122K | SEC | |
| Kong Garheng | Director | A — Grant or award | 24.2K | $0.00 | — | SEC | |
| PERSKY MARLA | Director | A — Grant or award | 24.2K | $0.00 | — | SEC | |
| HALKUFF DAWN | Director | A — Grant or award | 24.2K | $0.00 | — | SEC | |
| JOHNSON JOHN | Director | A — Grant or award | 24.2K | $0.00 | — | SEC | |
| JOHNSON JOHN | Director | S — Open-market sale | 15.0K | $6.09 | $91K | SEC | |
| Brady James Aloysius | Director | A — Grant or award | 24.2K | $0.00 | — | SEC | |
| BORMANN-KENNEDY BARBARA-JEAN ANNE | Director | S — Open-market sale | 16.0K | $6.09 | $98K | SEC | |
| PERSKY MARLA | Director | S — Open-market sale | 15.5K | $5.90 | $91K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Xeris Biopharma Holdings, Inc. (XERS). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| BORMANN-KENNEDY BARBARA-JEAN ANNE | 3 | $300K |
| Hecht Beth | 3 | $339K |
| PERSKY MARLA | 3 | $294K |
| JOHNSON JOHN | 3 | $294K |
| HALKUFF DAWN | 3 | $325K |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in XERS insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live XERS dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.